Ignite Creation Date:
2024-05-06 @ 12:25 PM
Last Modification Date:
2024-10-26 @ 12:58 PM
Study NCT ID:
NCT03757858
Status:
COMPLETED
Last Update Posted:
2024-02-07
First Post:
2018-11-27
Brief Title:
Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases
Sponsor:
Capital Medical University
Organization:
Capital Medical University
Study Overview
Official Title:
A Prospective Study of Hyperthermia Combined With Autologous Adoptive Cellular Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
It is a non-randomized pilot studyThe allocation will be determined by patients or their immediate family members who were cooperative with physicians interpretations on the disease progression and updated information of cutting of edge treatment the financial affordability availability of treatment plans possible tolerance or risks etcThe purpose of this study is to investigate the clinical efficacy and toxicity of autologous cellular immunotherapy combined with hyperthermia in abdominal and pelvic malignancies or metastases patients Furthermore to characterize response to different regimensthe investigators intent to explore the predictive and prognostic biomarker as well as the changes in immune repertoire
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None